Immunotherapy-Chemo cocktail aims to tame head and neck tumors
NCT ID NCT07214987
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tests a combination of the immunotherapy drug toripalimab plus two chemotherapy drugs (cisplatin and docetaxel) as an initial treatment for people with advanced head and neck cancer that has a specific marker (CPS-positive). The goal is to see if this approach is safe and tolerable before moving to curative treatments like surgery or radiation. About 26 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
toripalimab (an immunotherapy drug) combined with cisplatin and docetaxel (chemotherapy drugs)
What this could lead to
If successful, this could offer a safer and more effective induction therapy for patients with advanced head and neck cancer, potentially improving tumor control before definitive treatment.
What could go wrong
This is a small, early-phase trial with only 26 participants, so results may not apply broadly. The combination may still cause serious side effects, and it is not yet known if it will improve long-term outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.